Drugs used to treat hyperthyroidism include antithyroid medications like methimazole and propylthiouracil, radioactive iodine, and beta blockers to manage symptoms. These treatments reduce excess thyroid hormone production or block its effects.
Hyperthyroidism occurs when the thyroid gland produces too much thyroxine (T4) and triiodothyronine (T3). This overactivity speeds up metabolism, leading to weight loss, rapid heartbeat, anxiety, and tremors. The goal of treatment is to normalize hormone levels and relieve symptoms.
Antithyroid drugs inhibit the synthesis of thyroid hormones. Methimazole and propylthiouracil (PTU) are the two primary agents. Methimazole is preferred in most cases due to fewer side effects and once-daily dosing. PTU is reserved for specific situations, such as severe hyperthyroidism during pregnancy or thyroid storm.
Methimazole blocks the enzyme thyroid peroxidase, which is essential for adding iodine to tyrosine residues in the thyroid gland. Without this step, thyroid hormone synthesis halts. The drug reaches peak blood concentration within 1-2 hours and has a half-life of about 6 hours, allowing once-daily administration.
Propylthiouracil acts similarly but also inhibits the conversion of T4 to the more potent T3 in peripheral tissues. This dual action makes PTU effective in rapidly lowering active hormone levels. However, PTU carries a higher risk of liver toxicity, including rare but serious hepatotoxicity requiring monitoring.
A 2021 study published in The Journal of Clinical Endocrinology & Metabolism found that methimazole achieved euthyroid status in 78% of patients within 6 months, compared to 69% with PTU. Methimazole was associated with lower rates of agranulocytosis and rash, supporting its use as first-line therapy.
Three main categories of drugs are used: antithyroid agents, radioactive iodine, and symptom-relief medications. Each targets a different aspect of the condition.
| Treatment Type | Common Drug(s) | Primary Mechanism | Use Case |
|---|---|---|---|
| Antithyroid agents | Methimazole, Propylthiouracil | Inhibit thyroid hormone synthesis | First-line therapy; long-term control |
| Radioactive iodine | I-131 | Destroys overactive thyroid tissue | Definitive treatment; often used after medication fails |
| Symptom management | Propranolol, Atenolol | Blocks beta-adrenergic effects of excess thyroid hormone | Reduces tremors, palpitations, anxiety |
Radioactive iodine (RAI) is administered orally and selectively absorbed by thyroid cells. The radiation damages follicular cells, reducing hormone output. It's effective-over 90% of patients achieve normal thyroid function within 6-12 weeks. RAI is often used when medication fails or relapse occurs, or in older adults where surgery risks are high.
Propranolol, a beta blocker, doesn't affect hormone levels but alleviates symptoms like rapid heart rate, tremors, and nervousness. It's typically used short-term while other treatments take effect. A 2019 clinical trial showed propranolol reduced resting heart rate by an average of 22 beats per minute in hyperthyroid patients within 24 hours of dosing.
Many assume antithyroid drugs cure hyperthyroidism. They do not. These medications suppress hormone production but require ongoing use. Stopping them leads to relapse in up to 50% of patients within 12 months, according to the American Thyroid Association.
Another misconception is that radioactive iodine causes cancer. This is false. RAI does not increase cancer risk. The radiation dose is localized and minimal. The FDA confirms that RAI is safe and effective for treating hyperthyroidism when used appropriately.
PTU is sometimes mistakenly used in pregnant women beyond the first trimester. This is incorrect. Methimazole is contraindicated in early pregnancy due to risk of fetal malformations. PTU is preferred in the first trimester but switched to methimazole after week 12 due to PTU's higher risk of maternal liver injury.
A 34-year-old woman presents with a 3-month history of fatigue, weight loss, and palpitations. Lab tests show TSH <0.01 mIU/L, free T4 3.2 ng/dL, and T3 320 ng/dL. Ultrasound reveals a diffusely enlarged thyroid with increased vascularity. Diagnosis: Graves' disease.
She begins methimazole 10 mg daily. After 4 weeks, her TSH remains suppressed, but symptoms improve. Her doctor adds propranolol 10 mg twice daily to control heart rate. After 8 weeks, she achieves euthyroid status. Methimazole is continued for 12-18 months, with regular monitoring for agranulocytosis and liver enzymes.
If remission does not occur, radioactive iodine is offered. She declines due to concerns about hypothyroidism. After 18 months, methimazole is tapered and stopped. She remains euthyroid for 6 months before relapsing. Radioactive iodine is then recommended.
I managed a patient with recurrent hyperthyroidism who initially responded well to methimazole but relapsed after stopping. Switching to PTU improved control but caused elevated transaminases. We discontinued PTU and initiated RAI. The patient became hypothyroid within 3 months but reported better quality of life and no recurrence.
This case illustrates that treatment choice depends on individual factors: age, comorbidities, fertility plans, and tolerance. Methimazole is first-line, but alternatives exist based on patient-specific risks.
Understanding what drugs are used to treat hyperthyroidism involves recognizing that treatment is tailored to the cause, severity, and patient preferences. Methimazole and PTU reduce hormone production, RAI permanently destroys overactive tissue, and beta blockers manage symptoms. No single option fits all cases.